Research programme: vaccines - Akshaya Bio

Drug Profile

Research programme: vaccines - Akshaya Bio

Latest Information Update: 12 Aug 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Akshaya Bio
  • Developer Akshaya Bio; Nuron Biotech
  • Class Antimalarials; Cancer vaccines; Hepatitis B vaccines; Hepatitis C vaccines; Influenza virus vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Hepatitis B; Hepatitis C; HIV infections

Highest Development Phases

  • Preclinical Alphavirus infections; Hepatitis B; Hepatitis C; HIV infections; Influenza virus infections; Malaria
  • Research Cancer

Most Recent Events

  • 11 Aug 2016 Hepatitis B, Hepatitis C and HIV vaccines are available for licensing as of 31 Dec 2015.
  • 31 Dec 2015 Early research in Cancer in Canada (Parenteral) (3195687; before December 2015)
  • 31 Dec 2015 Akshaya Bio plans a phase Ia and a phase Ib trial for Hepatitis B
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top